<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138492">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298141</url>
  </required_header>
  <id_info>
    <org_study_id>HGT-REP-081</org_study_id>
    <nct_id>NCT01298141</nct_id>
  </id_info>
  <brief_title>A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease</brief_title>
  <official_title>A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal® (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe the safety of agalsidase alfa in Canadian patients
      with Fabry disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety of agalsidase alfa in patients with Fabry disease.

      Patients diagnosed with Fabry disease who meet current Canadian guidelines for enzyme
      replacement therapy will be eligible to enroll in the study and will receive agalsidase alfa
      at a dose of 0.2 mg/kg body weight administered by an IV infusion over 40 minutes every week
      or every other week, based on previous treatment.

      Shire has implemented a change to the drug substance manufacturing process. Safety data will
      be collected in patients receiving product manufactured with this process. There are no
      changes to the drug product formulation, manufacturing site, manufacturing process, and
      container closure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective of this study is to observe the safety of Replagal in Canadian patients with Fabry disease.</measure>
    <time_frame>Baseline to EOS</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>Replagal®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible patients may receive Replagal produced by the bioreactor process (AF Replagal) on this treatment plan until AF Replagal is commercially available for the patient, the patient's participation is discontinued, or the study is discontinued, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>agalsidase alfa</intervention_name>
    <description>Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)
Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly</description>
    <arm_group_label>Replagal®</arm_group_label>
    <other_name>Replagal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort 1:

          1. The patient has a documented diagnosis of Fabry disease.

          2. The patient is sufficiently compliant with study activities to participate in this
             treatment plan, as judged by the Investigator.

          3. The patient must meet current Canadian guidelines for enzyme replacement therapy for
             Fabry disease by meeting one of the following criteria:

               1. Age-adjusted glomerular filtration rate (GFR) &lt;80 ml/min or a decline in GFR of
                  &gt;10% which is sustained for 3 months and for which other causes of declining
                  renal function have been excluded by a nephrologist or any 2 of the following:

                    -  Isolated proteinuria ≥500 mg/day/1.73 m2 without other cause

                    -  Nephrogenic diabetes insipidus

                    -  Fanconi syndrome

                    -  Hypertension

               2. Evidence of cardiac involvement related to Fabry disease including any 2 of the
                  following:

                    -  Left ventricular (LV) wall thickness &gt;12 mm

                    -  Left ventricular hypertrophy (LVH) by electrocardiogram (ECG); Estes ECG
                       score must be &gt;5

                    -  Left ventricular mass index (LVMI) by 2D echocardiogram 20% above normal
                       for age

                    -  Diastolic filling abnormalities by 2D echocardiogram or by other accepted
                       measures of diastolic filling. E/A ration &gt;2.0 and deceleration time &lt;140
                       msec

                    -  Increase of LV mass of at least 5 g/m2/year, with three measurements over a
                       minimum of 12 months

                    -  Increase of left atrium (LA) size on 2D echo at least 10% above normal for
                       age. In parasternal long axis view (PLAX) &gt;33 mm; in four chamber view &gt;42
                       mm

                    -  Cardiac conduction and rhythm abnormalities: atrioventricular (AV) block,
                       short PR interval, left branch bundle block (LBBB), ventricular or atrial
                       tachyarrhythmias, sinus bradycardia (in the absence of drugs with negative
                       chronotropic activity)

                    -  Delayed posterolateral left ventricular wall late enhancement on MRI as
                       evidence of advanced cardiac disease with fibrosis

               3. Evidence of neurological involvement related to Fabry disease including 1 of the
                  following:

                    -  Stroke or transient ischemic attack (TIA) prior to the age of 55 documented
                       by a neurologist

                    -  Acute onset unilateral hearing loss

                    -  Acut monocular visual loss without other cause

               4. Chronic, intractable diarrhea and/or abdominal pain/cramps, refractory to
                  standard management for at least 6 months.

               5. Chronic, intractable neuropathic pain, refractory to analgesics and standard
                  pain management for at least 6 months.

             Cohort 2:

          4. Patient must have participated in Study REP001a.

        Exclusion Criteria:

          1. The patient has experienced an anaphylactic or anaphylactoid reaction or other
             infusion-related reaction which, in the opinion of the Investigator, precludes
             further treatment with agalsidase alfa or may interfere with the interpretation of
             the study.

          2. The patient is otherwise unsuitable for the study, in the opinion of the
             Investigator.

          3. The patient is enrolled in another clinical study, other than the Canadian Fabry
             Disease Initiative (CFDI).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <email>clinicaltransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aneal Khan, MD</last_name>
      <phone>(403)-955-7587</phone>
      <email>khaa@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Aneal Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2H7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Schellevis</last_name>
      <phone>780-248-1417</phone>
      <email>schellev@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Alicia Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Sirrs, MD</last_name>
      <phone>604-875-5965</phone>
      <email>sandra.sirrs@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Sandra Sirrs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1S1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Desrochers</last_name>
      <phone>204-787-4014</phone>
      <email>CDESROCHERS3@EXCHANGE.HSC.MB.CA</email>
    </contact>
    <investigator>
      <last_name>Cheryl Rockman-Greenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael West, MD</last_name>
      <phone>902-473-4023</phone>
      <email>mlwest@dal.ca</email>
    </contact>
    <investigator>
      <last_name>Michael West, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Izaak Walton Killam (IWK) Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Dyack, MD</last_name>
      <phone>902-470-8754</phone>
      <email>sarah.dyack@iwk.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Sarah Dyack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer MacKenzie, MD</last_name>
      <phone>613-548-2467</phone>
      <email>jennifer.mackenzie@queensu.ca</email>
    </contact>
    <investigator>
      <last_name>Jennifer MacKenzie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 2V5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Napier</last_name>
      <phone>519-685-8500 ext. 53510</phone>
      <email>Melanie.Napier@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Chitra Prasad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Fred A. Litwin Family Centre in Genetic Medicine</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Morel, MD</last_name>
      <phone>416-586-4800</phone>
      <phone_ext>4220</phone_ext>
      <email>chantal.morel@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Chantal Morel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Bichet, MD</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>2173</phone_ext>
      <email>daniel.bichet@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Bichet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke (CHUS)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Maranda, MD</last_name>
      <phone>416-813-5340</phone>
      <email>bruno.maranda@usherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>Bruno Maranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>February 15, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Replagal</keyword>
  <keyword>Enzyme Replacement Therapy</keyword>
  <keyword>agalsidase alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
